COMMITMENTS AND CONTINGENCIES - Narrative (Details)		3 Months Ended			9 Months Ended
	Aug. 27, 2021 USD ($) shares	Sep. 30, 2021 USD ($) renewalTerm	Dec. 31, 2020 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2021 USD ($) renewalTerm	Sep. 30, 2020 USD ($)
Loss Contingencies [Line Items]
Number of additional terms | renewalTerm		2			2
Renewal term		3 years			3 years
Lease expense		$ 16,000		$ 23,000	$ 100,000	$ 100,000
Issuance of common stock under license agreement		1,971,000
Research and development		10,222,000		1,281,000	25,112,000	6,657,000
Research and development expense, future payment, payment two	$ 107,500,000
Milestone payment	1,000,000.0
Voronoi Inc.
Loss Contingencies [Line Items]
Payments to acquire intangible assets	2,500,000
Issuance of common stock under license agreement	$ 2,000,000.0
Issuance of common stock under license agreement (in shares) | shares	2,816,901
Research and development		4,800,000			4,800,000
Research and development expense, future payment, payment one	$ 211,000,000.0
Bodor Laboratories, Inc.
Loss Contingencies [Line Items]
Research and development		$ 0	$ 1,000,000	1,500,000	0	1,500,000
Milestone payment				$ 500,000		$ 500,000
Cash payment					800,000
Payments for additional product approval					100,000
Value of shares issued in agreement					$ 1,000,000